pharmaceutical investing Ironwood and Alnylam Enter US GI Disease Education and Promotional Agreement
pharmaceutical investing Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
Arbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO (patisiran), for the Treatment of ATTR Amyloidosis
Quebec Innovative Materials:Advancing Canadian and American Natural Hydrogen for the Next Energy Cycle
